protein tyrosine phosphatase non-receptor type 9Genealiases: MEG2 · PTPMEG2
Q-omics provides the consensus-scored PTPN9 profile across patient tissues and cancer cell-line models. PTPN9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PTPN9 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PTPN9 RNA expression shows 20,612 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where PTPN9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN9 survival associations across molecular data types. PTPN9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN9 RNA expression–survival associations across cancer types. High PTPN9 expression shows unfavorable associations in ACC, UVM, MESO and LGG, but favorable associations in KIRC and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PTPN9 RNA expression.
This table summarizes PTPN9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PTPN9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN9 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, STAD, CHOL and LIHC. The HNSC box plot shows higher PTPN9 RNA expression in tumor versus normal tissue (log2 FC = +1.075, t-test p < 0.001).
This table shows molecular features associated with PTPN9 in patient tissues and cancer cell lines. In patient samples, PTPN9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
